Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexmedetomidine vs midazolam infusion in hypertensive intracerebral and intraventricular hemorrhage
IRCT20230101057010N1Phase 4Completed
- Sponsor
- Alborz University of Medical Sciences
- Start
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of dexmedetomidine and midazolam in intracerebral hemorrhage (ICH), Intraventricular hemorrhage (IVH) and intraparenchymal hematoma (IPH) (2 arms), sponsored by Alborz University of Medical Sciences. Primary endpoints: Agitation level and Hemodynamic changes. Started Dec 2023; status: completed.
02
Drugs
dexmedetomidinemidazolam
03
Conditions
intracerebral hemorrhage (ICH)Intraventricular hemorrhage (IVH)intraparenchymal hematoma (IPH)
Beyond the preview
Go deeper on IRCT20230101057010N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20230101057010N1.